Robert S. Negrin, professor of medicine at Stanford University, will serve as president of the American Society of Hematology for a year-long term through December 2026.
A phase III clinical trial will soon begin testing the evidence collected thus far that points to a stunning prospect: the COVID-19 vaccine—a widely accessible mRNA vaccine already on the market—could make checkpoint inhibitors work better for lung cancer and melanoma patients.
